Status: Recruiting
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS
The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).
Participants needed: 500
Trial details
Phase: Phase 2, Phase 3Age: 1-17Biological sex: AllType: InterventionalSponsor: Nationwide Children's HospitalUpdated: Mar 13, 2026Locations: 32
Eligibility criteria
≥ 40 weeks corrected gestational age to < 18 years; AND [+3]
Weight <3kg; OR [+11]